2011 Diabetes Vaccines 
pharmaphorum
MAY 17, 2021
The initial therapeutic focus is diabetes, with three insulin-based products in development. The Group’s third insulin product is a stable co-formulation of pramlintide and insulin, which has the potential to be a next generation treatment for both type 1 and type 2 diabetes.
Express Pharma
SEPTEMBER 11, 2023
1 Currently, as per a study done by Competition Commission of India, it was revealed that during 2011-2012, 47,478 brands were available with 2,871 formulations marketed in India, with an average of 17 brands for every formulation. As a result, during 2011—2012, approximately 235 drug brands were introduced monthly, with a total value of Rs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Putting Patients First Blog
SEPTEMBER 9, 2024
Mental health and substance use disorders significantly impact the quality of life and overall health of Medicare beneficiaries, often coexisting with other chronic conditions such as diabetes, cardiovascular disease, and chronic pain. The empirical evidence for the telemedicine intervention in diabetes management. 13 Bashshur, R.,
The Thyroid Pharmacist
NOVEMBER 8, 2024
15] Researchers believe that infections such as MAP might be a common pathogenic trigger behind multiple autoimmune and other diseases (including Hashimoto’s, rheumatoid arthritis, Crohn’s disease, type 1 diabetes, and possibly psoriasis) in genetically susceptible individuals. [16] Egyptian Journal of Obesity, Diabetes and Endocrinology.
Express Pharma
JANUARY 3, 2025
Epygen Biotech India was started in 2011, and today comprises an end to end biopharma R&D and manufacturing facility at MIDC Patalganga, near Mumbai, which develops and produces critical therapeutic proteins for both biosimilars and NBE space. Omicron BA.5).
Expert insights. Personalized for you.
52 
Let's personalize your content